T1	Intervention 634 806	Following baseline (6 weeks), patients entered a 19-week double-blind phase: 6-week titration (2 mg/week increments to target dose) followed by a 13-week maintenance period
T2	Intervention 565 632	randomized (1:1:1) to once-daily perampanel 8 mg, 12 mg, or placebo
